Across TCGA pan-cancer cohorts, LINC02731 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC02731 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher LINC02731 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC02731 expression acts as an unfavorable survival marker.
ESCA and UCEC are the cancer types where LINC02731 Mutation most reproducibly stratifies survival.